Therapeutic binding molecules
OwnerJosquin NYS, Albert THOM +7inventors
InventorsJosquin NYS, Albert THOM, Peter CARIUK, Darren SCHOFIELD, Aidan RILEY, Catherine HUNTINGTON, David REES, Lorraine IRVING, Matthew ROBINSON
Life of this patent
Estimating the term…
Abstract
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Claims18
A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of a binding molecule that binds to CCR9 and comprises a heavy chain variable (VH) region having a set of CDRs HCDR1, HCDR2 and HCDR3 and a light chain variable (VL) region having a set of CDRs LCDR1, LCDR2 and LCDR3, wherein
- (a) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO:
- 1, HCDR2 of SEQ ID NO:
- 2 and HCDR3 of SEQ ID NO:
- 3, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO:
- 4, LCDR2 of SEQ ID NO:
- 5 and LCDR3 of SEQ ID NO:
- 6;
- (b) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO:
- 7, HCDR2 of SEQ ID NO:
- 8 and HCDR3 of SEQ ID NO:
- 9, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO:
- 10, LCDR2 of SEQ ID NO:
- 11 and LCDR3 of SEQ ID NO:
- 12;
- or
- (c) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO:
- 13, HCDR2 of SEQ ID NO:
- 14 and HCDR3 of SEQ ID NO:
- 15, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO:
- 16, LCDR2 of SEQ ID NO:
- 17 and LCDR3 of SEQ ID NO:
- 18
- or wherein any one or more of said HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprises 1, 2 or 3 amino acid substitutions compared to said sequences.
A method of treating an inflammatory bowel disease in a subject, the method comprising administering to the subject an effective amount of a binding molecule that binds to CCR9 and comprises a heavy chain variable (VH) region having a set of CDRs HCDR1, HCDR2 and HCDR3 and a light chain variable (VL) region having a set of CDRs LCDR1, LCDR2 and LCDR3, wherein
- (a) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO:
- 1, HCDR2 of SEQ ID NO:
- 2 and HCDR3 of SEQ ID NO:
- 3, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO:
- 4, LCDR2 of SEQ ID NO:
- 5 and LCDR3 of SEQ ID NO:
- 6;
- (b) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO:
- 7, HCDR2 of SEQ ID NO:
- 8 and HCDR3 of SEQ ID NO:
- 9, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO:
- 10, LCDR2 of SEQ ID NO:
- 11 and LCDR3 of SEQ ID NO:
- 12;
- or
- (c) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO:
- 13, HCDR2 of SEQ ID NO:
- 14 and HCDR3 of SEQ ID NO:
- 15, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO:
- 16, LCDR2 of SEQ ID NO:
- 17 and LCDR3 of SEQ ID NO:
- 18 or wherein any one or more of said HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprises 1, 2 or 3 amino acid substitutions compared to said sequences.
A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of a binding molecule which binds to CCR9, wherein:
- (a) said binding molecule is capable of mediating antibody dependent cell-mediated cytotoxicity against a CCR9-expressing cell to which it binds
- (b) binding of the binding molecule to CCR9 does not induce internalisation of CCR9, and/or
- (c) the binding molecule competes with CC25 binding to CCR9, optionally human CCR9, optionally human CCR9A and CCR9B.
Dependencies are inferred from the claim text.